DUBLIN , April 7, 2023 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" report has been added to
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.
This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.
The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.
Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.
Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.
Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.
In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits:
In-depth understanding of royalty rate partnering deal trends since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
Insight into the royalty terms included in a licensing agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes:
Trends in royalty rates in the biopharma industry since 2010
Analysis of the structure of royalty clauses with real life case studies
Comprehensive listing of licensing deals which disclose royalty rates since 2010
Access to licensing contract documents which disclose royalty rates
The leading licensing deals by royalty rate value since 2010
Most active royalty rate disclosures since 2010
In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise royalty rates granted?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Actavis (acquired by Watson)
Advanced Dosage Forms
Afritex Medical Products
Allergan (name changed from Actavis)
American Type Culture Collection (ATCC)
Amorfix Life Sciences
Astellas Pharma Europe
Aurigene Discovery Technologies
Authentic Brands Group
Baker Brothers Investments
Baylor Research Institute
Beth Israel Deaconess Medical Center
Bioprocess Capital Ventures
Biotechnology Value Fund
BrainStorm Cell Therapeutics
Cancer Prevention Pharmaceuticals
Castle Creek Pharmaceuticals
Cell Cure Neurosciences
Chong Kun Dang
Chongqing Jingdong Pharmaceutical
Clalit Health Services
Cures Within Reach
Cutanea Life Sciences
Dana-Farber Cancer Institute
DNA Biomedical Solutions
Dr. Falk Pharma
Dr. Reddy's Laboratories
Drugs for Neglected Diseases Initiative
Eagle Pharmaceuticals (US)
Fairview Health System
Fresenius Kabi Pharmaceuticals
Glenmark Generics Inc USA
Government of Israel
Hail First Pharma
Hainan Sihuan Pharmaceutical
Hefei Life Science
Hefei Tianhui Incubation of Technologies
HIBM Research Group
Hoffmann La Roche
Horizon Pharma Inc
Icahn School of Medicine at Mount Sinai
Ice + Jam
Internet Marketing Consortium
Inverness Medical Innovations
Israeli National Authority for Technological Innovation
Jiangsu Lianhuan Pharmaceuticals
Jiangsu NHWA Pharmaceutical
John Morley Foods
Kraig Biocraft Laboratories
Kwang Dong Pharmaceutical
Kyowa Hakko Kirin
Lifestyle Delivery Systems
Massachusetts General Hospital
McEwen Centre for Regenerative Medicine
Medical Technologies Innovation Asia
Medicines Patent Pool Foundation
Merck and Co
Ministry of Health
Labor and Welfare
Munich Leukemia Laboratory
Nantong Jinghua Pharmaceutical
National Green Biomed
NeuroVive Pharmaceutical Asia
New York University
Novartis Vaccines and Diagnostics
Oculus Innovative Sciences
One Way Liver Genomics (OWL)
Pan-Provincial Vaccine Enterprise
Parnell Pharmaceutical Holdings
Professional Compounding Centers of America
Prometic Life Sciences
Quick Med Technologies
Reedy Creek Investments
RST Biomedikal Sanayi
Sheba Medical Center
Shenzhen BioScien Pharmaceuticals
St. Jude Children's Research Hospital
St Jude Medical
Swedish Orphan Biovitrum
Technion Research and Development Foundation
Teva Pharmaceutical Industries
Texas A&M University
The Regents of the University of California
Titterington Veterinary Services
Tiziana Life Sciences
University Health Network
University of Alberta
University of California
University of Central Florida Research Foundation
University of Colorado
University of Florida Research Foundation
University of Geneva
University of Missouri
University of Notre of Dame
University of Pennsylvania
University of Western Sydney
University of Zurich
Upstream Peripheral Technologies
VBL Therapeutics (dba)
WAVE Life Sciences
Wisconsin Alumni Research Foundation
World Class Extractions
Yeda Research and Development Company
For more information about this report visit
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
SOURCE Research and Markets
Kevin Leininger Transitions to Executive Chairman
Additional Executive Promotions in Solutions Delivery and India Operations
PHILADELPHIA, Jan. 20, 2023 /PRNewswire/ -- IntegriChain, delivering pharma's only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced the appointment of Joshua Halpern, co-founder and current President and Chief Operating Officer, to the role of Chief Executive Officer (CEO) effective February 1, 2023. Kevin Leininger, current CEO, will transition to the role of Executive Chairman and remain active in the business strategy. In addition, Sachin Sadekar has been promoted to Senior Vice President and Managing Director, India Operations, and Jeff Tanner has been promoted to Senior Vice President of Solution Delivery, also effective February 1, 2023.
"Over the last two years, IntegriChain has made incredible strides in our growth trajectory and ability to deliver solutions that overcome key commercialization challenges for our pharma customers, and we owe so much of our success to Kevin's leadership," said Halpern. "We've created the first comprehensive platform for data-driven drug commercialization and access; we've become the industry's largest provider of Contracts & Pricing managed services; we've amassed an outstanding team of world-class strategic consultants and hands-on operational consultants that spans the full spectrum of drug commercialization; we've built innovative data and technology solutions that are used in the day-to-day operations of more than 250 manufacturers; and we've become a highly visible and impactful company in the pharma commercial services market. I am forever indebted to Kevin as my mentor and partner. I'm excited about IntegriChain's future as we begin our next chapter and look forward to helping the company achieve its next set of objectives in my new role."
"Josh and I founded IntegriChain 16 years ago and have led the company's growth side by side," said Leininger. "He truly understands the challenges that pharma manufacturers face and has played a vital role in delivering a transformative data, technology, service, and consulting platform to the industry. I am proud of the outstanding team that will take IntegriChain forward, I am utterly confident in Josh's ability to seamlessly lead IntegriChain to the next level, and I consider myself lucky to continue to play an important role on the board going forward."
About Josh Halpern
Josh Halpern co-founded IntegriChain in 2006 and brings more than 20 years of experience in pharmaceutical commercialization, data, and analytics. As the company's Chief Executive Officer, he will be responsible for corporate management and leadership of IntegriChain's global workforce and strategic planning for the company, focusing on driving long-term business value across the company's operations, its go-to-market strategy and teams, and its technology organization and roadmaps. From IntegriChain's founding through its initial venture capital-backed growth, Halpern led the development of IntegriChain's market leading channel and patient data aggregation solutions. Following the company's partnership with Accel-KKR in 2016, Halpern has been a key leader in five successful acquisitions and their integration within the IntegriChain business and IntegriChain's ICyte technology platform. In that time, IntegriChain has grown to become a visionary technology, data, consulting, and outsourcing platform for data-driven drug commercialization with more than 600 team members and 400 customers. Halpern is a frequent industry speaker and author on data-driven strategies for patient access and therapy commercialization. He earned his bachelor's degree at Princeton University.
"I'm also very happy to announce the promotion of Sachin Sadekar, who has led the incredible growth of our India operations over the past three years, and Jeff Tanner, who has been instrumental to our ability to deliver the ICyte Platform to top-30 Pharma manufacturers," Halpern added. "Sachin's experience and insights have been critical to the success of this important team that is vital to our data and managed services businesses as well as our technology innovation and implementation. Similarly, we could not have the upmarket customer success we have without Jeff and his outstanding abilities in standing up enterprise-class commercialization and access systems."
Sadekar leads IntegriChain's India operations, including Engineering, Product Management, and Managed Services. With more than 25 years of experience, Sadekar is a seasoned technology and managed services executive with significant Life Sciences experience. Prior to joining IntegriChain, Sadekar served as an executive at Cognizant, CPG Business at Wipro Technologies, NuTech Consulting, and Infosys. His full bio is available here.
Tanner leads IntegriChain's Solutions Delivery practice, responsible for all new customer implementations, platform expansions, and systems integration. Over his 25-year career, he has delivered on more than 100 revenue management and major technology migrations. He was previously with Cumberland Life Sciences and Revitas (now Model N). His full bio is available here.
IntegriChain sits at the heart of Pharma manufacturers' interactions with the ecosystem that distributes, pays for, and supports therapy utilization. IntegriChain's technology, data, consulting, and outsourcing solutions help more than 400 Pharma manufacturers build and execute data-driven strategies for drug commercialization. The company's ICyte Platform uniquely integrates the financial, operational, and commercial business processes that underpin therapy access, helping manufacturers remove barriers to demand realization while remaining sound stewards of business profitability. With ICyte, pharmaceutical innovators can achieve strategic commercial advantage and better commercial outcomes by digitalizing daily and recurring business activities and by orchestrating those activities with increasingly diagnostic and predictive analytics. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA; and Pune, India. For more information, visit , or follow on Twitter @IntegriChain and on LinkedIn.
Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, [email protected]
CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from the sale of non-PuraPly products was $61.2 million, not $32.0 million. The corrected release follows:
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three months ended March 31, 2021.
First Quarter 2021 Financial Results Summary:
First Quarter 2021 Highlights:
“2021 is off to a strong start,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “We delivered significant year-over-year revenue growth across both our Advanced Wound Care and Surgical and Sports Medicine portfolios driven by strong sales of our amniotic and PuraPly products. We are pleased that successful execution of our PuraPly strategy generated PuraPly sales well ahead of our expectations. With continued strong execution against our commercial strategy, we also significantly improved our profitability.”
Mr. Gillheeney, Sr. continued: “The fundamentals of our business and strategy remain strong and we are well positioned to continue to deliver strong operating and financial performance over the balance of 2021. We remain confident in our ability to execute our long-term strategic plan as we deliver on our mission to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care.”
First Quarter 2021 Results:
The following table represents net revenue by product grouping for the three months ended March 31, 2021 and March 31, 2020, respectively:
Net revenue for the first quarter of 2021 was $102.6 million, compared to $61.7 million for the first quarter of 2020, an increase of $40.8 million, or 66%. The increase in net revenue was driven by a $39.4 million increase, or 77%, in net revenue of Advanced Wound Care products and a $1.4 million increase, or 13%, in net revenue of Surgical & Sports Medicine products, compared to the first quarter of 2020.
Gross profit for the first quarter of 2021 was $77.1 million, or 75% of net revenue, compared to $42.9 million, or 70% of net revenue, for the first quarter of 2020, an increase of $34.1 million, or 79%. The increase in gross profit resulted primarily from increased sales volume due to the strength in our Advanced Wound Care and Surgical & Sports Medicine products as well as a shift in product mix to our higher gross margin products.
Operating expenses for the first quarter of 2021 were $64.4 million, compared to $58.0 million for the first quarter of 2020, an increase of $6.4 million, or 11%. R&D expense was $6.2 million for the first quarter of 2021, compared to $5.4 million in the first quarter of 2020, an increase of $0.8 million, or 15%. Selling, general and administrative expenses were $58.2 million, compared to $52.6 million in the first quarter of 2020, an increase of $5.6 million, or 11%.
Operating income for the first quarter of 2021 was $12.6 million, compared to an operating loss of $15.1 million for the first quarter of 2020, an increase of $27.7 million.
Total other expenses, net, for the first quarter of 2021 were $2.5 million, compared to $1.2 million for the first quarter of 2020, an increase of $1.3 million, or 107%. The increase was primarily due to a $1.3 million gain for the three months ended March 31, 2020 related to the settlement of the deferred acquisition consideration dispute with the sellers of NuTech Medical.
Net income for the first quarter of 2021 was $9.9 million, or $0.07 per share, compared to a net loss of $16.3 million, or $0.16 per share, for the first quarter of 2020, an increase of $26.3 million, or $0.23 per share.
Adjusted EBITDA of $16.0 million for the first quarter of 2021, compared to Adjusted EBITDA loss of $10.9 million for the first quarter of 2020, an increase of $27.0 million.
As of March 31, 2021, the Company had $78.0 million in cash and restricted cash and $88.1 million in debt obligations, of which $18.4 million were capital lease obligations, compared to $84.8 million in cash and restricted cash and $84.8 million in debt obligations, of which $15.1 million were capital lease obligations as of December 31, 2020.
Fiscal Year 2021 Guidance:
For the twelve months ended December 31, 2021, the Company now expects:
First Quarter 2021 Earnings Conference Call:
Financial results will be reported after the market closes on Monday, May 10. Management will host a conference call at 5:00 p.m. Eastern Time on May 10 to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may dial 866-795-3142 (409-937-8908 for international callers) and provide access code 9199306. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.
For those unable to participate, a replay of the call will be available for two weeks at 855-859-2056 (404-537-3406 for international callers); access code 9199306. The webcast will be archived at investors.organogenesis.com.
Non-GAAP Financial Measures
Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.
The following is a reconciliation of GAAP net income (loss) to non-GAAP EBITDA and non-GAAP Adjusted EBITDA for each of the periods presented:
(1) Amount reflects the gain recognized related to the settlement of the deferred acquisition consideration dispute with the sellers of NuTech Medical in February 2020. See Note 18 to the unaudited financial statements included in our quarterly report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”). (2) Amount reflects the collection of certain notes receivable from related parties previously reserved. See Note 19 to the unaudited financial statements included in our Form 10-Q. (3) Amount reflects the change in the fair value of the Earnout liability in connection with the CPN acquisition. See Note 3 to the unaudited financial statements included in our Form 10-Q. (4) Amount reflects employee retention and other benefit-related costs related to the Company’s restructuring activities. See Note 12 to the unaudited financial statements included in our Form 10-Q.(5) Amount reflects the legal, advisory and other professional fees incurred in the three months ended March 31, 2020 related directly to the CPN acquisition. See Note 3 to the unaudited financial statements included in our Form 10-Q.(6) Amount reflects the cancellation fee for terminating certain product development and consulting agreements the Company inherited from NuTech Medical. See Note 18 to the unaudited financial statements included in our Form 10-Q.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue for fiscal 2021 and the breakdown of such revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories as well as the estimated revenue contribution of its PuraPly products. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products and the impact to the Company of the loss of preferred “pass through” status for PuraPly AM and PuraPly in 2020; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of Affinity in sufficient quantities to meet demand; (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; and (11) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2020 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
About Organogenesis Holdings Inc. Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .